Crestline Management’s Sana Biotechnology SANA Stock Holding History

Crestline Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.64M	Hold	755,736	–	–	4.93%	2
2026 Q1	$2.18M	Sell	755,736 -465,201	-38%	-$1.83M	4.7%	2
2025 Q4	$4.97M	Sell	1,220,937 -600,000	-33%	-$2.69M	9.32%	2
2025 Q3	$6.46M	Sell	1,820,937 -600,000	-25%	-$2.17M	11.13%	2
2025 Q2	$6.61M	Sell	2,420,937 -370,000	-13%	-$763K	10.56%	2
2025 Q1	$4.69M	Sell	2,790,937 -70,000	-2%	-$196K	7.41%	2
2024 Q4	$4.66M	Sell	2,860,937 -224,687	-7%	-$670K	0.16%	149
2024 Q3	$12.8M	Sell	3,085,624 -140,000	-4%	-$735K	0.67%	24
2024 Q2	$17.6M	Sell	3,225,624 -140,000	-4%	-$1.12M	1.37%	8
2024 Q1	$33.7M	Hold	3,365,624	–	–	2.97%	3
2023 Q4	$13.7M	Hold	3,365,624	–	–	1.17%	15
2023 Q3	$13M	Hold	3,365,624	–	–	1.52%	8
2023 Q2	$20.1M	Buy	3,365,624 +154,687	+5%	+$891K	2.09%	3
2023 Q1	$10.5M	Sell	3,210,937 -154,687	-5%	-$618K	1.25%	15
2022 Q4	$13.3M	Hold	3,365,624	–	–	1.95%	4
2022 Q3	$20.2M	Hold	3,365,624	–	–	2.73%	2
2022 Q2	$21.6M	Buy	3,365,624 +154,687	+5%	+$985K	2.82%	2
2022 Q1	$26.5M	Hold	3,210,937	–	–	3.18%	2
2021 Q4	$49.7M	Hold	3,210,937	–	–	3.71%	6
2021 Q3	$72.3M	Hold	3,210,937	–	–	6.8%	2
2021 Q2	$63.1M	Buy	+3,210,937	New	+$72.8M	5.44%	2

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Crestline Management's SANA Position: Q2 2026 in Review

Crestline Management held its Sana Biotechnology (SANA) position steady in Q2 2026 at 755,736 shares worth $2.64M. The position accounts for 4.93% of the portfolio, ranked #2.

Crestline Management first reported a position in SANA in Q2 2021 and has held it in 21 quarters since. The position peaked at $72.3M in Q3 2021. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

Crestline Management held 755,736 shares of Sana Biotechnology worth $2.64M as of Q2 2026.
Crestline Management left its Sana Biotechnology share count unchanged in Q2 2026.
Sana Biotechnology made up 4.93% of Crestline Management's portfolio in Q2 2026, its #2 holding.
Crestline Management first reported a position in Sana Biotechnology in Q2 2021 and has held it in 21 quarters since.
Crestline Management's Sana Biotechnology position peaked at $72.3M in Q3 2021.
211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Crestline Management's 13F filing for Q2 2026, filed 14 Aug 2026.